Scancell Holdings Plc Change of Date for Final Results (7012P)
October 11 2023 - 1:00AM
UK Regulatory
TIDMSCLP
RNS Number : 7012P
Scancell Holdings Plc
11 October 2023
11 October 2023
Scancell Holdings plc
("Scancell" or the "Company")
Change of Date for Final Results and Investor Presentation
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
today announces a revised date for the publication of its results
for the year ended 30 April 2023.
The audit of the Group's Annual Report & Accounts is well
advanced, however, the Group's auditor, BDO LLP, has requested more
time to complete their standard audit. As a result, the Company
will now announce its results on 24 October 2023, a delay to the
previously planned date of 12 October 2023.
Professor Lindy Durrant, Chief Executive Officer, and Sath
Nirmalananthan, Chief Financial Officer, will host an analyst
briefing at 10:00am BST on the revised date of the results at the
offices of ICR Consilium, 85 Gresham St, London, EC2V 7NQ.
The Company will also be holding a presentation for investors on
24 October 2023 at 4:30pm BST via the Investor Meet Company
platform.
The presentation is open to all existing and potential
shareholders and will be followed by a Q&A session. Questions
can be submitted ahead of the event via the Investor Meet Company
dashboard up until 9.00am BST on 23 October 2023, or at any time
during the live presentation.
To sign up to Investor Meet Company for free and add to register
for Scancell's presentation , please visit:
https://www.investormeetcompany.com/scancell-holdings-plc/register-investor
A copy of the presentation will also be made available on the
Company's news section following the presentation.
-ENDS-
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3709 5700
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser
and Joint Broker) +44 (0) 20 7710 7600
Nicholas Moore/Samira Essebiyea/William Palmer-Brown
(Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium +44 (0) 20 3709 5700
Mary-Jane Elliott/Matthew Neal/Chris Welsh scancell@consilium-comms.com
About Scancell
Scancell is a clinical stage biopharmaceutical company that is
leveraging its proprietary research, built up over many years of
studying the human adaptive immune system, to generate novel
medicines to treat significant unmet needs in cancer and infectious
disease. The Company is building a pipeline of innovative products
by utilising its four technology platforms: Moditope (R) and
ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for
antibodies.
Adaptive immune responses include antibodies and T cells (CD4
and CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique
approach is that its innovative products target modifications of
proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody
(R) ) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that
are added onto proteins and / or lipids (GlyMab(R) ) or enhances
the potency of antibodies and their ability to directly kill tumour
cells (AvidiMab (R) ).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORZZMMGLGGGFZM
(END) Dow Jones Newswires
October 11, 2023 02:00 ET (06:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024
